Skip to main content
Year archive

BioLineRx Ltd. — 2022 filings

All 74 regulatory filings released by BioLineRx Ltd. (BLRX) in 2022, sourced directly from the official regulator.

74 Filings
2022 Period
2022 filings (74)
Filing Released Lang
6-K
Foreign Filer Report
2022-12-20 English
Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
Regulatory Filings
2022-12-20 English
Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
Report Publication Announcement
2022-12-20 English
6-K
Foreign Filer Report
2022-11-15 English
Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
Interim / Quarterly Report 9M 2022
2022-11-15 English
Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
Report Publication Announcement
2022-11-15 English
6-K
Foreign Filer Report
2022-11-10 English
Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
Regulatory Filings
2022-11-10 English
Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
Report Publication Announcement
2022-11-10 English
Receipt of Nasdaq Minimum Bid Price Notification
Regulatory Filings
2022-11-06 English
Receipt of Nasdaq Minimum Bid Price Notification
Report Publication Announcement
2022-11-06 English
6-K
Foreign Filer Report
2022-11-04 English
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society o
Regulatory Filings
2022-11-03 English
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society o
Report Publication Announcement
2022-11-03 English
6-K
Foreign Filer Report
2022-11-03 English
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
Regulatory Filings
2022-09-27 English
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
Report Publication Announcement
2022-09-27 English
6-K
Foreign Filer Report
2022-09-27 English
FORM 6-K- BioLineRx completed $15 Million direct offering of ADSs and warrants
Regulatory Filings
2022-09-21 English
FORM 6-K- BioLineRx completed $15 Million direct offering of ADSs and warrants
Report Publication Announcement
2022-09-21 English
6-K
Foreign Filer Report
2022-09-21 English
PROSPECTUS SUPPLEMENT dated September 18, 2022
Capital/Financing Update
2022-09-20 English
PROSPECTUS SUPPLEMENT dated September 18, 2022
Report Publication Announcement
2022-09-20 English
424B5
Prospectus
2022-09-20 English
BioLineRx Announces $15 Million Registered Direct Offering
Capital/Financing Update
2022-09-19 English
BioLineRx Announces $15 Million Registered Direct Offering
Capital/Financing Update
2022-09-19 English
6-K
Foreign Filer Report
2022-09-19 English
6-K
Foreign Filer Report
2022-09-15 English
BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital
Capital/Financing Update
2022-09-15 English
BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital
Capital/Financing Update
2022-09-15 English
6-K
Foreign Filer Report
2022-09-12 English
BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
Regulatory Filings
2022-09-12 English
BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
Regulatory Filings
2022-09-12 English
20-F/A
Annual Report FY 2021
2022-09-09 English
Form 20-F/A
Regulatory Filings FY 2021
2022-09-09 English
Form 20-F/A
Report Publication Announcement
2022-09-09 English
6-K
Foreign Filer Report
2022-08-16 English
Second Quarter 2022 Financial Results and Provides Corporate Update
Interim / Quarterly Report Q2 2022
2022-08-16 English
Second Quarter 2022 Financial Results and Provides Corporate Update
Report Publication Announcement
2022-08-16 English
6-K
Foreign Filer Report
2022-07-05 English
Results of Annual General Meeting which was held on July 3, 2022
AGM Information
2022-07-05 English
Results of Annual General Meeting which was held on July 3, 2022
AGM Information
2022-07-05 English
6-K
Foreign Filer Report
2022-06-28 English
ollaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)
Regulatory Filings
2022-06-28 English
ollaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)
Report Publication Announcement
2022-06-28 English
6-K
Foreign Filer Report
2022-06-16 English
BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer
Board/Management Information
2022-06-16 English
BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer
Board/Management Information
2022-06-16 English
Convening of annual meeting to be held on 03/07/2022 -Scribal error
Proxy Solicitation & Information Statement
2022-05-29 English
Convening of annual meeting to be held on 03/07/2022 -Scribal error
AGM Information
2022-05-29 English
Convening of annual meeting to be held on 03/07/2022 -Scribal error
AGM Information
2022-05-29 English
6-K
Foreign Filer Report
2022-05-27 English
Convening of annual meeting to be held on 03/07/2022
Proxy Solicitation & Information Statement
2022-05-27 English
Convening of annual meeting to be held on 03/07/2022
AGM Information
2022-05-27 English
Convening of annual meeting to be held on 03/07/2022
AGM Information
2022-05-27 English
6-K
Foreign Filer Report
2022-05-11 English
FORM 6-K-Reports First Quarter 2022 Financial Results
Interim / Quarterly Report Q1 2022
2022-05-11 English
FORM 6-K-Reports First Quarter 2022 Financial Results
Earnings Release Q1 2022
2022-05-11 English
20-F
Annual Report FY 2021
2022-03-16 English
Form 20-F 2021
Annual Report FY 2021
2022-03-16 English
Form 20-F 2021
Report Publication Announcement
2022-03-16 English
BioLineRx Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update
Earnings Release Q4 2021
2022-03-16 English
BioLineRx Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update
Report Publication Announcement
2022-03-16 English
6-K
Foreign Filer Report
2022-03-16 English
6-K
Foreign Filer Report
2022-03-03 English
BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization
Regulatory Filings
2022-03-03 English
BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization
Regulatory Filings
2022-03-03 English
AMENDMENT NO. 2 TO SCHEDULE 13G
Major Shareholding Notification
2022-02-11 English
6-K
Foreign Filer Report
2022-01-24 English
BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors
Regulatory Filings
2022-01-24 English
BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors
Report Publication Announcement
2022-01-24 English
6-K
Foreign Filer Report
2022-01-18 English
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patient
Regulatory Filings
2022-01-18 English
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patient
Report Publication Announcement
2022-01-18 English